{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:49:02Z","timestamp":1793116142680,"version":"4.5.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"DocTIS"},{"name":"European Union\u2019s Horizon 2020","award":["848028"],"award-info":[{"award-number":["848028"]}]},{"DOI":"10.13039\/501100012093","name":"VHIR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012068","name":"Health and Care Research Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Current treatments for rheumatoid arthritis (RA) and psoriatic arthritis (PsA) reduce disease activity but often fail to achieve sustained remission. The Decision on Optimal Combinatorial Therapies in Immune-mediated inflammatory diseases using Systems approaches (DocTIS) program has shown that additive anti-inflammatory effects in patients with arthritis can be achieved by combining tumour necrosis factor (TNF) and interleukin (IL)-6 inhibitor therapies. The goal was to provide proof-of-principle evaluation of whether combining TNF and IL-6 inhibitors shows a signal of activity on remission outcomes in RA and PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single-arm, multicentre, adaptive basket trial recruiting 20 patients with RA and 20 with PsA and including 24\u2009weeks of treatment and 10\u2009weeks of safety follow-up. Eligible participants on TNF for \u22656\u2009weeks will proceed with the addition of IL-6 inhibitor (tocilizumab) at 162\u2009mg every 2\u2009weeks for 8\u2009weeks, increasing to weekly dosing in weeks 9\u201324 if well tolerated. The primary outcome is remission at 24\u2009weeks (Clinical Disease Activity Index score \u22642.8 in RA and Disease Activity in PsA score &amp;lt;4). Secondary outcomes include safety, tolerability and disease activity assessments. Using Simon\u2019s two-stage design (80% power, one-sided \u03b1\u2009=\u20090.10), the trial aims to detect an increase in remission (10% to 30%). An interim futility analysis will occur after seven participants per basket reach 24\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Findings from this proof-of-principle study will inform the feasibility and design of future randomised trials evaluating combination biologic therapy in inflammatory arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study registration<\/jats:title>\n                    <jats:p>www.isrctn.com; ISRCTN50666516<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rap\/rkag036","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T10:17:07Z","timestamp":1774088227000},"source":"Crossref","is-referenced-by-count":1,"title":["Decision on Optimal Combinatorial Therapies in Immune-mediated inflammatory diseases using Systems approaches (DocTIS): protocol for a single-arm, adaptive basket trial in rheumatoid and psoriatic arthritis"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9571-8274","authenticated-orcid":false,"given":"Rory","family":"Sheppard","sequence":"first","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3664-4302","authenticated-orcid":false,"given":"Myrsini","family":"Gianatsi","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"King","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6934-2928","authenticated-orcid":false,"given":"David","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8274-9696","authenticated-orcid":false,"given":"Philip","family":"Pallmann","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University , Cardiff,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5515-3854","authenticated-orcid":false,"given":"Sara Marsal","family":"Barril","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital Universitari Vall d\u2019Hebron and Vall d\u2019Hebron Institut de Recerca , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-8609","authenticated-orcid":false,"given":"Ernest","family":"Choy","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, School of Medicine, Cardiff University , Cardiff,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"2026042914264726900_rkag036-B1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.31138\/mjr.20230801.oo","article-title":"Overview of rheumatoid arthritis and scientific understanding of the disease","volume":"34","author":"Jahid","year":"2023","journal-title":"Mediterr J Rheumatol"},{"key":"2026042914264726900_rkag036-B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026042914264726900_rkag036-B3","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2026042914264726900_rkag036-B4","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/rheumatology\/ker365","article-title":"Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone","volume":"51","author":"Rosen","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2026042914264726900_rkag036-B5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5114\/reum.2020.101400","article-title":"Conventional disease-modifying agents in rheumatoid arthritis - a review of their current use and role in treatment algorithms","volume":"58","author":"Padjen","year":"2020","journal-title":"Reumatologia"},{"key":"2026042914264726900_rkag036-B6","doi-asserted-by":"publisher","first-page":"104497","DOI":"10.1016\/j.phrs.2019.104497","article-title":"Role of biological agents in treatment of rheumatoid arthritis","volume":"150","author":"Law","year":"2019","journal-title":"Pharmacol Res"},{"key":"2026042914264726900_rkag036-B7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1177\/2040622315582354","article-title":"Psoriatic arthritis: latest treatments and their place in therapy","volume":"6","author":"Kang","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"key":"2026042914264726900_rkag036-B8","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","article-title":"Tumor necrosis factor inhibitors in psoriatic arthritis","volume":"10","author":"Mantravadi","year":"2017","journal-title":"Exp Rev Clin Pharmacol"},{"key":"2026042914264726900_rkag036-B9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026042914264726900_rkag036-B10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026042914264726900_rkag036-B11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3899\/jrheum.151132","article-title":"Achievement of remission and low disease activity definitions in patients with rheumatoid arthritis in clinical practice: results from the NOR-DMARD Study","volume":"43","author":"Uhlig","year":"2016","journal-title":"J Rheumatol"},{"key":"2026042914264726900_rkag036-B12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-017-1424-8","article-title":"Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice","volume":"19","author":"van Mens","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2026042914264726900_rkag036-B13","doi-asserted-by":"publisher","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","article-title":"Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis","volume":"7","author":"Aaltonen","year":"2012","journal-title":"PLoS One"},{"key":"2026042914264726900_rkag036-B14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/cer-2017-0106","article-title":"Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis","volume":"7","author":"Murray","year":"2018","journal-title":"J Comp Effect Res"},{"key":"2026042914264726900_rkag036-B15","doi-asserted-by":"publisher","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"2026042914264726900_rkag036-B16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2016-209784","article-title":"Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis","volume":"76","author":"Low","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026042914264726900_rkag036-B17","doi-asserted-by":"publisher","first-page":"vii5","DOI":"10.1093\/rheumatology\/key059","article-title":"20 years of experience with tumour necrosis factor inhibitors: what have we learned?","volume":"57","author":"Caporali","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026042914264726900_rkag036-B18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2026042914264726900_rkag036-B19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026042914264726900_rkag036-B20","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1136\/annrheumdis-2017-212845","article-title":"Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration","volume":"77","author":"Lauper","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026042914264726900_rkag036-B21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/annrheumdis-2012-202470","article-title":"Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement","volume":"72","author":"Schoels","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026042914264726900_rkag036-B22","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026042914264726900_rkag036-B23","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/J.ARD.2025.06.869","article-title":"ABS0280 Unveiling synergistic drug combinations for immune-mediated inflammatory diseases: insights from the DoCTIS consortium using systems biology approaches","volume":"84","author":"Juli\u00e0","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026042914264726900_rkag036-B24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/S41927-021-00192-5\/TABLES\/4","article-title":"Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential","volume":"5","author":"Grayling","year":"2021","journal-title":"BMC Rheumatol"},{"key":"2026042914264726900_rkag036-B25","doi-asserted-by":"publisher","first-page":"e081477","DOI":"10.1136\/BMJ-2024-081477","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomised trials","volume":"389","author":"Chan","year":"2025","journal-title":"BMJ"},{"key":"2026042914264726900_rkag036-B26","doi-asserted-by":"publisher","first-page":"m115","DOI":"10.1136\/BMJ.M115","article-title":"The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design","volume":"369","author":"Dimairo","year":"2020","journal-title":"BMJ"},{"key":"2026042914264726900_rkag036-B27","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2026042914264726900_rkag036-B28","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026042914264726900_rkag036-B29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s10067-006-0298-y","article-title":"A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis","volume":"26","author":"Borman","year":"2007","journal-title":"Clin Rheumatol"},{"key":"2026042914264726900_rkag036-B30","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.100857","article-title":"Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study","volume":"38","author":"Cauli","year":"2011","journal-title":"J Rheumatol"},{"key":"2026042914264726900_rkag036-B31","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3899\/jrheum.171183","article-title":"Physician\u2019s global assessment in psoriatic arthritis: a multicenter GRAPPA study","volume":"45","author":"Cauli","year":"2018","journal-title":"J Rheumatol"},{"key":"2026042914264726900_rkag036-B32","first-page":"S4","article-title":"Measures of functional status and quality of life in rheumatoid arthritis: health assessment questionnaire disability index (HAQ), modified health assessment questionnaire (MHAQ), multidimensional health assessment questionnaire (MDHAQ), health assessment","volume":"63(Suppl 11)","author":"Maska","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2026042914264726900_rkag036-B33","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/acr.20282","article-title":"Measuring fatigue in rheumatoid arthritis: A cross-sectional study to evaluate the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional questionnaire, visual analog scales, and numerical rating scales","volume":"62","author":"Nicklin","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2026042914264726900_rkag036-B34","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/ard.2008.100271","article-title":"Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative","volume":"68","author":"Gossec","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026042914264726900_rkag036-B35","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","article-title":"A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative","volume":"73","author":"Gossec","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026042914264726900_rkag036-B36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/oxfordjournals.pubmed.a024606","article-title":"A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies?","volume":"19","author":"Jenkinson","year":"1997","journal-title":"J Public Health"},{"key":"2026042914264726900_rkag036-B37","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/imj.14046","article-title":"Comorbidity in psoriatic arthritis and rheumatoid arthritis","volume":"48","author":"Sinnathurai","year":"2018","journal-title":"Intern Med J"},{"key":"2026042914264726900_rkag036-B38","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3389\/fphar.2019.00965","article-title":"Adverse events in patients with rheumatoid arthritis and psoriatic arthritis receiving long-term biological agents in a real-life setting","volume":"10","author":"De Camargo","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026042914264726900_rkag036-B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"2026042914264726900_rkag036-B40","doi-asserted-by":"publisher","first-page":"e70174","DOI":"10.1002\/SIM.70174","article-title":"Confidence intervals for adaptive trial designs I: a methodological review","volume":"44","author":"Robertson","year":"2025","journal-title":"Stat Med"},{"key":"2026042914264726900_rkag036-B41","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.1002\/SIM.9867","article-title":"A comparison of Bayesian information borrowing methods in basket trials and a novel proposal of modified exchangeability-nonexchangeability method","volume":"42","author":"Daniells","year":"2023","journal-title":"Stat Med"},{"key":"2026042914264726900_rkag036-B42","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/J.1365-2125.2012.04167.X","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2026042914264726900_rkag036-B43","doi-asserted-by":"crossref","first-page":"107111","DOI":"10.1016\/j.cmpb.2022.107111","article-title":"Development of a REDCap-based workflow for high-volume relational data analysis on real-time data in a medical department using open source software","volume":"226","author":"Rovera","year":"2022","journal-title":"Comput Methods Programs Biomed"},{"key":"2026042914264726900_rkag036-B44","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41393-018-0169-9","article-title":"REDCap: web-based software for all types of data storage and collection","volume":"56","author":"Harvey","year":"2018","journal-title":"Spinal Cord"},{"key":"2026042914264726900_rkag036-B45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13063-016-1425-y","article-title":"What are the roles and valued attributes of a Trial Steering Committee? Ethnographic study of eight clinical trials facing challenges","volume":"17","author":"Daykin","year":"2016","journal-title":"Trials"},{"key":"2026042914264726900_rkag036-B46","first-page":"143","article-title":"Independent data monitoring committees: an update and overview","volume":"33","author":"Sartor","year":"2015","journal-title":"Urol Oncol Semin Orig Investig"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkag036\/67454300\/rkag036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/2\/rkag036\/67454300\/rkag036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/2\/rkag036\/67454300\/rkag036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:26:54Z","timestamp":1777487214000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkag036\/8532537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkag036","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rkag036"}}